Valneva initie une étude sur l’homogénéité des lots cliniques de Phase 3 de son candidat vaccin à injection unique contre le chikungunya

NEXT STORY
Immunicum Announces Encouraging Signs of Survival Benefit in Phase II MERECA Trial of Ilixadencel in Kidney Cancer
PREV STORY
NMPA Approves Toripalimab in Patients with Recurrent or Metastatic Nasopharyngeal Carcinoma after Failure of at Least Two Lines of Prior Systemic Therapy
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Trillium Therapeutics Reports Second Quarter 2020 Financial and Operating Results

author_avatar
NASDAQ Market News

Phase 2 Clinical Trial of Bermekimab Shows Potential New Standard of Care for Treatment of Hidradenitis Suppurativa, Including Significant Pain Reduction without Antibiotics

author_avatar
NASDAQ Market News

Nanobiotix Announces First Ever Radioenhancer to Receive European Market Approval

author_avatar
NASDAQ Market News